NCT04655313

Maximal Usage Pharmacokinetics and Safety of ARQ-151 in Children With Plaque Psoriasis (ARQ-151-215)

An Open Label, 4-Week, Phase 2, Maximal Usage Pharmacokinetics and Safety Study of ARQ-151 Cream 0.3% Administered QD in Pediatric Subjects (Ages 6 to 11 Years Old) With Plaque Psoriasis

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 20 (actual)
• Sponsor: Arcutis Biotherapeutics, Inc. · Industry
• Sex: All
• Age: 6 Years – 11 Years
• Healthy volunteers: Not accepted

Summary

This is a Phase 2, open label, maximal usage PK and safety study of ARQ-151 cream 0.3% in pediatric subjects (ages 6 to 11 years old) with plaque psoriasis:

Conditions

• Psoriasis
• Plaque Psoriasis

Interventions

Type	Name	Description
DRUG	ARQ-151 cream 0.3%	ARQ-151 cream 0.3% applied to chronic plaque psoriasis lesions once a day for 4 weeks

Timeline

• Start date: 2020-11-30
• Primary completion: 2022-01-12
• Completion: 2022-01-12
• First posted: 2020-12-07
• Last updated: 2023-12-15
• Results posted: 2023-12-15

Locations

17 sites across 3 countries: United States, Canada, Dominican Republic

Regulatory

• FDA-regulated drug study